---
document_datetime: 2025-12-02 05:01:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rapamune.html
document_name: rapamune.html
version: success
processing_time: 0.1343623
conversion_datetime: 2025-12-27 20:12:02.594374
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rapamune

[RSS](/en/individual-human-medicine.xml/65618)

##### Authorised

This medicine is authorised for use in the European Union

sirolimus Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rapamune](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79308)
- [More information on Rapamune](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rapamune is a medicine used to prevent the body from rejecting a newly transplanted kidney. It is used in adults who are at a low to moderate risk of rejection. It is recommended that Rapamune is used with ciclosporin and corticosteroids (other medicines to prevent organ rejection) for two to three months. Rapamune can then be used for continuing treatment with corticosteroids, but only if ciclosporin treatment can be stopped.

Rapamune is also used for treating patients with sporadic lymphangioleiomyomatosis (S-LAM) with moderate lung disease or worsening lung function. S-LAM is a rare lung disease that causes worsening symptoms such as shortage of breath and occurs mainly in women who are at an age when they can have children.

Rapamune contains the active substance sirolimus.

Expand section

Collapse section

## How is Rapamune used?

Rapamune treatment should be started by and remain under the guidance of a doctor who is a qualified specialist in transplantation. The medicine can only be obtained with a prescription.

Rapamune is available as an oral solution (1 mg/ml) and tablets (0.5, 1 and 2 mg).

To prevent organ rejection, the first dose is usually 6 mg given soon after the transplantation followed by 2 mg once a day. The doctor will adjust the dose to achieve appropriate levels of sirolimus in the patient's blood.

To treat patients with S-LAM, the dose of Rapamune is 2 mg daily and after 10 to 20 days the doctor will adjust the dose to achieve appropriate levels of sirolimus in the patient's blood.

For more information about using Rapamune, see the package leaflet or contact your doctor or pharmacist.

## How does Rapamune work?

The active substance in Rapamune, sirolimus, is an immunosuppressant (a medicine that reduces the activity of the immune system). In the body, sirolimus attaches to a protein inside cells to make a 'complex'. This complex then blocks another protein called 'mammalian target of rapamycin' (mTOR). Since mTOR is involved in the multiplication of activated T?lymphocytes (white blood cells that are responsible for attacking the transplanted organ), Rapamune reduces the number of these cells, reducing the risk of organ rejection.

In S-LAM, mTOR is overactive, causing excessive multiplication of cells that cause the disease. By blocking mTOR, Rapamune reduces the multiplication of these cells.

## What benefits of Rapamune have been shown in studies?

**Prevention of rejection**

Rapamune was more effective than placebo (a dummy treatment) or azathioprine (another immunosuppressive medicine) in two main studies involving a total of 1,295 patients who were having a kidney transplant. All patients were also treated with ciclosporin and corticosteroids and were at low to moderate risk of rejection. The main measure of effectiveness was the number of treatment failures (rejection or loss of the new kidney, or death) after 6 months. In the first study, treatment failed in 19% (53 out of 284) of the patients adding Rapamune after 6 months, compared with 32% (52 out of 161) of those adding azathioprine. In the second study, treatment failed in 30% (68 out of 277) of the patients adding Rapamune, compared with 48% (62 out of 130) of those adding placebo.

Two additional studies looked at Rapamune as continuing treatment for up to 5 years in 765 patients who were able to stop ciclosporin after 2 to 3 months. Rapamune was effective in helping the new kidney to survive, with an improvement in how well it worked and an improvement in blood pressure when ciclosporin treatment was stopped.

**Treatment of S-LAM**

Rapamune was more effective than placebo in improving lung function in a study involving 81 patients with S-LAM. The main measure of effectiveness was a change of FEV 1 (the maximum volume of air a person can breathe out in 1 second). FEV 1 improved by an average of 1 ml per month in patients treated with Rapamune compared with a worsening by 12 ml per month in patients receiving placebo.

## What are the risks associated with Rapamune?

The most common side effects with Rapamune (which may affect more than 1 in 10 people) are infections, fever, slow wound healing, low counts of various blood cells, blood tests showingaltered levels of various substances (including low potassium and phosphate; raised fats, cholesterol, glucose and markers for tissue breakdown and for liver and kidney function), diabetes, lymphocele (collection of lymph fluid usually in the lower belly), pain in various parts of the body, rapid heartbeat, raised blood pressure, problems affecting the gut, proteinuria (protein in the urine), menstrual disorders, oedema (swelling because of fluid build-up), rash and acne.

Patients allergic to peanut or soya must not take Rapamune oral solution because the solution contains soya oil.

For the full list of side effects and restrictions of Rapamune, see the package leaflet.

## Why is Rapamune authorised in the EU?

The European Medicines Agency considered that Rapamune is effective for the prevention of rejection of a transplanted kidney in patients at low to moderate risk of rejection. The Agency noted that no medicinal product has been approved for the treatment of S-LAM and Rapamune's effect on lung function is considered important. The Agency decided that Rapamune's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Rapamune?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rapamune have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rapamune are continuously monitored. Side effects reported with Rapamune are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rapamune

Rapamune received a marketing authorisation valid throughout the EU on 14 March 2001.

Rapamune : EPAR - Medicine overview

English (EN) (102.44 KB - PDF)

**First published:** 27/11/2008

**Last updated:** 13/09/2018

[View](/en/documents/overview/rapamune-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-835)

български (BG) (137.63 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/bg/documents/overview/rapamune-epar-medicine-overview_bg.pdf)

español (ES) (103.75 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/es/documents/overview/rapamune-epar-medicine-overview_es.pdf)

čeština (CS) (123.03 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/cs/documents/overview/rapamune-epar-medicine-overview_cs.pdf)

dansk (DA) (103.63 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/da/documents/overview/rapamune-epar-medicine-overview_da.pdf)

Deutsch (DE) (104.22 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/de/documents/overview/rapamune-epar-medicine-overview_de.pdf)

eesti keel (ET) (102.31 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/et/documents/overview/rapamune-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.86 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/el/documents/overview/rapamune-epar-medicine-overview_el.pdf)

français (FR) (104.33 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/fr/documents/overview/rapamune-epar-medicine-overview_fr.pdf)

hrvatski (HR) (119.13 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/hr/documents/overview/rapamune-epar-medicine-overview_hr.pdf)

italiano (IT) (103.76 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/it/documents/overview/rapamune-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (124.7 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/lv/documents/overview/rapamune-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (122.25 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/lt/documents/overview/rapamune-epar-medicine-overview_lt.pdf)

magyar (HU) (121.34 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/hu/documents/overview/rapamune-epar-medicine-overview_hu.pdf)

Malti (MT) (132.91 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/mt/documents/overview/rapamune-epar-medicine-overview_mt.pdf)

Nederlands (NL) (103.74 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/nl/documents/overview/rapamune-epar-medicine-overview_nl.pdf)

polski (PL) (122.88 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/pl/documents/overview/rapamune-epar-medicine-overview_pl.pdf)

português (PT) (103.71 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/pt/documents/overview/rapamune-epar-medicine-overview_pt.pdf)

română (RO) (121.02 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/ro/documents/overview/rapamune-epar-medicine-overview_ro.pdf)

slovenčina (SK) (121.59 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/sk/documents/overview/rapamune-epar-medicine-overview_sk.pdf)

slovenščina (SL) (118.35 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/sl/documents/overview/rapamune-epar-medicine-overview_sl.pdf)

Suomi (FI) (103.34 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/fi/documents/overview/rapamune-epar-medicine-overview_fi.pdf)

svenska (SV) (103.28 KB - PDF)

**First published:**

27/11/2008

**Last updated:**

13/09/2018

[View](/sv/documents/overview/rapamune-epar-medicine-overview_sv.pdf)

Rapamune : EPAR - Risk-management-plan summary

English (EN) (88.34 KB - PDF)

**First published:** 08/08/2018

**Last updated:** 08/06/2022

[View](/en/documents/rmp-summary/rapamune-epar-risk-management-plan-summary_en.pdf)

## Product information

Rapamune : EPAR - Product Information

English (EN) (1.05 MB - PDF)

**First published:** 16/06/2008

**Last updated:** 17/09/2025

[View](/en/documents/product-information/rapamune-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-857)

български (BG) (577.4 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/bg/documents/product-information/rapamune-epar-product-information_bg.pdf)

español (ES) (527.27 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/es/documents/product-information/rapamune-epar-product-information_es.pdf)

čeština (CS) (540.52 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/cs/documents/product-information/rapamune-epar-product-information_cs.pdf)

dansk (DA) (546.29 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/da/documents/product-information/rapamune-epar-product-information_da.pdf)

Deutsch (DE) (551.67 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/de/documents/product-information/rapamune-epar-product-information_de.pdf)

eesti keel (ET) (509.21 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/et/documents/product-information/rapamune-epar-product-information_et.pdf)

ελληνικά (EL) (1.27 MB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/el/documents/product-information/rapamune-epar-product-information_el.pdf)

français (FR) (542.44 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/fr/documents/product-information/rapamune-epar-product-information_fr.pdf)

hrvatski (HR) (578.71 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/hr/documents/product-information/rapamune-epar-product-information_hr.pdf)

íslenska (IS) (544.67 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/is/documents/product-information/rapamune-epar-product-information_is.pdf)

italiano (IT) (527.83 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/it/documents/product-information/rapamune-epar-product-information_it.pdf)

latviešu valoda (LV) (537.4 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/lv/documents/product-information/rapamune-epar-product-information_lv.pdf)

lietuvių kalba (LT) (507.27 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/lt/documents/product-information/rapamune-epar-product-information_lt.pdf)

magyar (HU) (555.81 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/hu/documents/product-information/rapamune-epar-product-information_hu.pdf)

Malti (MT) (629.37 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/mt/documents/product-information/rapamune-epar-product-information_mt.pdf)

Nederlands (NL) (533.27 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/nl/documents/product-information/rapamune-epar-product-information_nl.pdf)

norsk (NO) (536.35 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/no/documents/product-information/rapamune-epar-product-information_no.pdf)

polski (PL) (566.11 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/pl/documents/product-information/rapamune-epar-product-information_pl.pdf)

português (PT) (531.78 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/pt/documents/product-information/rapamune-epar-product-information_pt.pdf)

română (RO) (537.21 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/ro/documents/product-information/rapamune-epar-product-information_ro.pdf)

slovenčina (SK) (1.2 MB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/sk/documents/product-information/rapamune-epar-product-information_sk.pdf)

slovenščina (SL) (543.99 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/sl/documents/product-information/rapamune-epar-product-information_sl.pdf)

Suomi (FI) (530.86 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/fi/documents/product-information/rapamune-epar-product-information_fi.pdf)

svenska (SV) (516.8 KB - PDF)

**First published:**

16/06/2008

**Last updated:**

17/09/2025

[View](/sv/documents/product-information/rapamune-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000278463 11/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rapamune : EPAR - All Authorised presentations

English (EN) (21.44 KB - PDF)

**First published:** 11/09/2008

**Last updated:** 13/09/2010

[View](/en/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-800)

български (BG) (84.06 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/bg/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.42 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/es/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_es.pdf)

čeština (CS) (85.5 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/cs/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.79 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/da/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.04 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/de/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.91 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/et/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (90.61 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/el/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_el.pdf)

français (FR) (12.91 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/fr/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (35.03 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/hr/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.96 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/is/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_is.pdf)

italiano (IT) (12.45 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/it/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (81.82 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/lv/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (84.99 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/lt/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (81.83 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/hu/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (82.99 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/mt/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.33 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/nl/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.24 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/no/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_no.pdf)

polski (PL) (84 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/pl/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.87 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/pt/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_pt.pdf)

română (RO) (78.62 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/ro/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (81.6 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/sk/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (48.83 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/sl/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.68 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/fi/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.98 KB - PDF)

**First published:**

11/09/2008

**Last updated:**

13/09/2010

[View](/sv/documents/all-authorised-presentations/rapamune-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rapamune Active substance sirolimus International non-proprietary name (INN) or common name sirolimus Therapeutic area (MeSH)

- Graft Rejection
- Kidney Transplantation

Anatomical therapeutic chemical (ATC) code L04AH01

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued.

Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.

## Authorisation details

EMA product number EMEA/H/C/000273 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 16/11/2000 Marketing authorisation issued 13/03/2001 Revision 49

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rapamune : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (247.03 KB - PDF)

**First published:** 04/02/2025

**Last updated:** 17/09/2025

[View](/en/documents/procedural-steps-after/rapamune-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Rapamune : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (342.78 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 04/02/2025

[View](/en/documents/procedural-steps-after/rapamune-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Rapamune-H-C-PSUSA-00002710-202009 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/425641/2021

English (EN) (125.53 KB - PDF)

**First published:** 28/07/2021

[View](/en/documents/scientific-conclusion/rapamune-h-c-psusa-00002710-202009-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Rapamune-H-C-273-II-0164 : EPAR - Assessment Report - Variation

Reference Number: EMA/493416/2018

English (EN) (1.91 MB - PDF)

**First published:** 08/08/2018

**Last updated:** 08/08/2018

[View](/en/documents/variation-report/rapamune-h-c-273-ii-0164-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of opinion for Rapamune

Adopted

Reference Number: EMA/CHMP/229070/2018

English (EN) (68.66 KB - PDF)

**First published:** 29/06/2018

**Last updated:** 29/06/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-rapamune_en.pdf)

Rapamune : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (102.45 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 08/08/2006

[View](/en/documents/steps-after-cutoff/rapamune-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

Rapamune-H-C-273-X-0021 : EPAR - Scientific Discussion - Extension

Adopted

English (EN) (199.77 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 08/08/2006

[View](/en/documents/scientific-discussion-variation/rapamune-h-c-273-x-0021-epar-scientific-discussion-extension_en.pdf)

## Initial marketing authorisation documents

Rapamune : EPAR - Procedural steps taken before authorisation

English (EN) (39.85 KB - PDF)

**First published:** 16/06/2009

**Last updated:** 16/06/2009

[View](/en/documents/procedural-steps/rapamune-epar-procedural-steps-taken-authorisation_en.pdf)

Rapamune : EPAR - Scientific Discussion

English (EN) (507.46 KB - PDF)

**First published:** 08/08/2006

**Last updated:** 08/08/2006

[View](/en/documents/scientific-discussion/rapamune-epar-scientific-discussion_en.pdf)

#### News on Rapamune

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-june-2018) 29/06/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2017) 21/07/2017

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Rapamune : EPAR - Product information - tracked changes

English (EN) (9.68 MB - DOCX)

**First published:** 17/09/2025

[View](/en/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-991)

български (BG) (353.61 KB - DOCX)

**First published:**

17/09/2025

[View](/bg/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_bg.docx)

español (ES) (302.13 KB - DOCX)

**First published:**

17/09/2025

[View](/es/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_es.docx)

čeština (CS) (311.28 KB - DOCX)

**First published:**

17/09/2025

[View](/cs/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (295.01 KB - DOCX)

**First published:**

17/09/2025

[View](/da/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (299.16 KB - DOCX)

**First published:**

17/09/2025

[View](/de/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (279.92 KB - DOCX)

**First published:**

17/09/2025

[View](/et/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (9.73 MB - DOCX)

**First published:**

17/09/2025

[View](/el/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_el.docx)

français (FR) (299.79 KB - DOCX)

**First published:**

17/09/2025

[View](/fr/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (265.16 KB - DOCX)

**First published:**

17/09/2025

[View](/hr/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (318.43 KB - DOCX)

**First published:**

17/09/2025

[View](/is/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_is.docx)

italiano (IT) (293.33 KB - DOCX)

**First published:**

17/09/2025

[View](/it/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (296.65 KB - DOCX)

**First published:**

17/09/2025

[View](/lv/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (272.48 KB - DOCX)

**First published:**

17/09/2025

[View](/lt/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (312.66 KB - DOCX)

**First published:**

17/09/2025

[View](/hu/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (343.14 KB - DOCX)

**First published:**

17/09/2025

[View](/mt/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (283.45 KB - DOCX)

**First published:**

17/09/2025

[View](/nl/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (318.66 KB - DOCX)

**First published:**

17/09/2025

[View](/no/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_no.docx)

polski (PL) (339.88 KB - DOCX)

**First published:**

17/09/2025

[View](/pl/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_pl.docx)

português (PT) (293.14 KB - DOCX)

**First published:**

17/09/2025

[View](/pt/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_pt.docx)

română (RO) (320.4 KB - DOCX)

**First published:**

17/09/2025

[View](/ro/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (9.72 MB - DOCX)

**First published:**

17/09/2025

[View](/sk/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (313.49 KB - DOCX)

**First published:**

17/09/2025

[View](/sl/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (313.55 KB - DOCX)

**First published:**

17/09/2025

[View](/fi/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (285.14 KB - DOCX)

**First published:**

17/09/2025

[View](/sv/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_sv.docx)

#### More information on Rapamune

- [Rapamune - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/rapamune)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Paediatrics](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A65)

**This page was last updated on** 17/09/2025

## Share this page

[Back to top](#main-content)